FeesSafety
Pluang+

Four Dividend Kings remain strong but PepsiCo's dividend payout is riskier than others.

Market News
09 Oct 2026, 15:20 WIB
24/7 Wall Street
View Source
Neutral
Four Dividend Kings remain strong but PepsiCo's dividend payout is riskier than others.

Four Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, and PepsiCo—continue to deliver steady dividends, crucial for retirees relying on portfolio income. Johnson & Johnson and Procter & Gamble show very safe dividend payouts with healthy free cash flow and strong balance sheets, while Coca-Cola remains safe despite higher payout ratios. PepsiCo, however, faces risk as its dividend consumes nearly all free cash flow, requiring strong cash flow conversion to maintain its streak. All four companies raised dividends modestly this year, maintaining long-term payout growth streaks, but PepsiCo's financial cushion is thinner compared to the others.

Johnson & Johnson, Procter & Gamble, Coca-Cola, and PepsiCo show varied investor interest on Pluang, with Johnson & Johnson seeing 96% buy orders and a dividend yield of 2.09%. PepsiCo offers the highest dividend yield at 4.61% but has a shorter typical hold time of 107 days. These figures are current as of Oct 09, 2026 19:11 WIB.

More News (JNJ)

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson continues to show resilience with a 64-year dividend increase streak and raised full-year revenue and earnings guidance for 2026. Despite its strong business fundamentals and leadership in pharmaceuticals and medical devices, the st...

Company Fundamentals
Bullish
8 hours ago
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer are key healthcare giants with differing strategies: J&J balances drug innovation and medical devices, while Pfizer focuses on oncology and obesity treatments. J&J reported stronger revenue growth and higher net income, w...

Market News
Neutral
9 hours ago
Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson continues to lead in pharmaceuticals and medical devices, boasting a 64-year streak of dividend increases. The company recently raised its full-year revenue and earnings guidance, reflecting solid business performance. However, its ...

Company Fundamentals
Bullish
13 hours ago
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer, two healthcare giants, are taking different growth paths heading into 2027. Johnson & Johnson maintains a balanced business with strong pharmaceutical and medical device segments, showing steady revenue growth and a soli...

Market News
Neutral
14 hours ago
Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

The Dow Jones Industrial Average fell nearly 950 points on Friday, entering correction territory by closing over 10% below its record high. The sell-off was driven by continued weakness in technology stocks, including a 14% drop in Nvidia after SEC a...

Bearish
17 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App